Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.30 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6862733 | 1.00 | GLP1R (0.33) | GLP1RCA12CA1CA2CA9 | |
| SCHEMBL6139837 | 0.86 | C3AR1 (0.33) | CA12CA1CA2CA9F2 | |
| SCHEMBL5038292 | 0.84 | TGM2 (0.42) | CA1CA2CPB2 | |
| SCHEMBL6862744 | 0.84 | TGM2 (0.42) | CA1CA2CPB2 | |
| SCHEMBL6139416 | 0.81 | CPB2 (0.36) | CA12CA1CA2CA9CPB2 | |
| SCHEMBL5131021 | 0.79 | C3AR1 (0.34) | CA12CA1CA2CA9F2 | |
| Lysine SCHEMBL5035367 | 0.77 | GSR (0.43) | — | |
| SCHEMBL5035365 | 0.77 | TGM2 (0.45) | CPB2 | |
| SCHEMBL25309372 | 0.76 | FOLH1 (0.47) | GLP1RSLC6A5DGAT1 | |
| SCHEMBL30914214 | 0.76 | FOLH1 (0.47) | GLP1RSLC6A5DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307237-B9 | COMPLEXES CONTAINING PERFLUOROALKYL WITH POLAR RADICALS, METHOD FOR THE PRODUCTION AND USE THEREOF | BAYER SCHERING PHARMA AG (DE) | 2008-01-09 | — | — | EP | disclosed |
| EP-1307237-B1 | COMPLEXES CONTAINING PERFLUOROALKYL WITH POLAR RADICALS, METHOD FOR THE PRODUCTION AND USE THEREOF | BAYER SCHERING PHARMA AG (DE) | 2007-04-11 | — | — | EP | disclosed |
| US-20050074409-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-04-07 | — | — | US | disclosed |
| US-6818203-B2 | COMPLEXES HAVE CRITICAL MICELLE FORMATION CONCENTRATION, HYDRODYNAMIC MICELLE DIAMETER, AND PROTON RELAXIVITY IN PLASMA CONTRAST MEDIA IN MR IMAGING | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-11-16 | — | — | US | disclosed |
| US-6676928-B2 | AS CONTRAST MEDIA FOR THE VISUALIZATION OF MALIGNANT TUMORS, LYMPH NODES AND NECROTIC TISSUE | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-01-13 | — | — | US | disclosed |
| EP-1307237-A2 | COMPLEXES CONTAINING PERFLUOROALKYL WITH POLAR RADICALS, METHOD FOR THE PRODUCTION AND USE THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-07 | — | — | EP | disclosed |
| US-20030072713-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-04-17 | — | — | US | disclosed |
| US-20020076380-A1 | Perfluoroalkyl-containing complexes with polar radicals, process for their production and their use | SCHERING AG (DE) | 2002-06-20 | — | — | US | disclosed |
| WO-2002013875-A2 | COMPLEXES CONTAINING PERFLUOROALKYL WITH POLAR RADICALS, METHOD FOR THE PRODUCTION AND USE THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030072713-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | FABP3, PRF1, PTDSS1 | GLP1R 2940/4885CA12 534/4885CA1 205/4885 |
| US-20050074409-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | FABP3, PRF1, MALT1 | GLP1R 1956/4885CA12 535/4885CA1 247/4885 |
| US-20020076380-A1 | Perfluoroalkyl-containing complexes with polar radicals, process for their production and their use | FFAR1, FGB, FCGRT | GLP1R 1878/4885CA12 2659/4885CA1 1877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.